Menu Search
Equities

Viridian Therapeutics Inc

VRDN:NAQ

Viridian Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)20.20
  • Today's Change0.58 / 2.96%
  • Shares traded858.29k
  • 1 Year change+28.83%
  • Beta1.0570
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Viridian Therapeutics Inc's revenues fell -82.28% from 1.77m to 314.00k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 129.87m to a larger loss of 237.73m.
Gross margin--
Net profit margin-85,127.15%
Operating margin-93,722.52%
Return on assets-46.71%
Return on equity-77.05%
Return on investment-49.63%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Viridian Therapeutics Inc fell by 52.75m. Cash Flow from Financing totalled 225.67m or 71,869.43% of revenues. In addition the company used 184.17m for operations while cash used for investing totalled 94.25m.
Cash flow per share-4.25
Price/Cash flow per share--
Book value per share8.94
Tangible book value per share8.94
More ▼

Balance sheet in USDView more

Viridian Therapeutics Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio18.55
Quick ratio--
Total debt/total equity0.029
Total debt/total capital0.0282
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.